Pro­to­cols: Tri­ci­da bags $55M round for CKD drug; $MRK gets a 'break­through’;

South San Fran­cis­co-based Tri­ci­da has brought its to­tal fundrais­ing to $95 mil­lion, with a new $55 mil­lion C round ear­marked to fund its work on an ex­per­i­men­tal ther­a­py for chron­ic kid­ney dis­ease. Com­pa­ny CEO Ger­rit Klaern­er says the biotech is “on track to com­plete a first-in-hu­man 100 pa­tient phase 1/2 study of its lead com­pound, TRC101, in 2016, and is prepar­ing to dis­cuss the safe­ty and ef­fi­ca­cy re­sults from the study with the FDA in a Type B meet­ing lat­er this year.” Lon­gi­tude Cap­i­tal led the round with par­tic­i­pa­tion by new in­vestor Vi­vo Cap­i­tal and ex­ist­ing in­vestors Or­biMed, Sib­ling Cap­i­tal Ven­tures and Limu­lus Ven­ture Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER